Norsk Medisinsk Syklotronsenter

Makes short-lived PET radiopharmaceuticals for diagnostic imaging, serving clinics and pharma partners from Oslo

Oslo, NorwayFounded 2003syklotronsenteret.no Website technologies

Highlights

New on EvolcAdded 2026-10-28

About Norsk Medisinsk Syklotronsenter

Norsk Medisinsk Syklotronsenter (NMS), also known as Syklotronsenteret, develops and manufactures short-lived radiopharmaceutical products used in PET imaging examinations. The listed products include fludeoxyglucose (18F), flutemetamol (18F), sodium fluoride (18F), PSMA-1007 (18F), oxygen-15 (15O) and Axumin (fluciklovin, 18F).

Customers include healthcare professionals and clinics in Norway, as well as pharmaceutical companies. Some products are manufactured on contract for GE Healthcare and Blue Earth Diagnostics Ltd. The company participates in European Radiopharmacy Technology (ERT), a joint venture based in Germany. It is also linked to the Oslo Imaging and Therapy Laboratory (OITL), a multidisciplinary platform for molecular targeted imaging and therapy research.

The company was founded in 2003 and is headquartered in Oslo. Its stated goals include expanding into international markets, increasing capacity, and developing new diagnostic and therapeutic radiopharmaceuticals. In September 2026 it signed a letter of intent with Technopolis. Open positions are advertised on Finn.no.

Product: Short-lived PET radiopharmaceuticals (18F and 15O labelled) for diagnostic imaging, including contract manufacturing for other companies.

Public tenders won

1 tender won since 1 Jan 2024 from 1 public buyer in Sweden, worth 85.0M SEK as awarded. From EU award notices (TED) that name Norsk Medisinsk Syklotronsenter by its registry number.

17 Apr 2026 Region Västmanland · Upphandling -Temporär PET/CT · 85.0M SEK notice

Open tenders like these →

Jobs at Norsk Medisinsk Syklotronsenter

No open positions listed right now.

More biotech & pharma companies

Nuclithera
Targeted radiopharmaceuticals for patients with metastatic and difficult-to-treat cancers
Oslo, NorwayBiotech & pharmaFounded 2023
Young companyNew on Evolc
Nykode Therapeutics
Develops immunotherapies for patients with cancer and autoimmune diseases using a modular biotech platform
Oslo, NorwayBiotech & pharmaFounded 2006
New on Evolc
Oncosyne
Tumoroid-based drug screening and predictive diagnostics for pharmaceutical companies and cancer care providers
Oslo, NorwayBiotech & pharmaFounded 20201 open job
New on Evolc
Pharma Holdings
Develops intranasal antimicrobial drugs for patients with respiratory viral infections
Tromsø, NorwayBiotech & pharmaFounded 2016
New on Evolc
Pluvia
Develops small-molecule drugs for patients with rare protein-misfolding disorders, starting with phenylketonuria (PKU)
Bergen, NorwayBiotech & pharmaFounded 2015
New on Evolc
Previwo
Probiotic products for farmed salmon and trout that strengthen fish health in aquaculture
Oslo, NorwayBiotech & pharmaFounded 2013
New on Evolc